Validation of the Chinese version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (the CHO-KLAT)

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2014-11, Vol.20 (6), p.794-799
• Main Authors: Wu, R., Zhang, J., Sun, J., Zhou, M., Wu, J. S., Li, N., Li, X., Luke, K. H., Poon, M.-C., Blanchette, V. S., Young, N. L.
• Format: Article
• Language: English
• Subjects: Adolescent; Child; China; Female; haemophilia; Hemophilia A - diagnosis; Hemophilia A - drug therapy; Hemophilia A - epidemiology; Hemophilia B - diagnosis; Hemophilia B - drug therapy; Hemophilia B - epidemiology; Humans; Male; outcome measurement; paediatrics; Public Health Surveillance; Quality of Life; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.12489

Summary It is important to assess the health‐related quality of life outcomes of boys in China, but there are no tools validated for this purpose. The objective of the study was to assess the validity of the Simplified Chinese version of the CHO‐KLAT2.0. We recruited 60 boys with either haemophilia A (HA) or haemophilia B (HB) and their parents from four regions in China, and assessed the validity of CHO‐KLAT compared to the PedsQL. All participants complete the CHO‐KLAT a second time 1–2 weeks later to assess reliability. The boys ranged in age from 7 to 18 (mean = 12.4; SD = 3.03) years. The severity distribution was: mild (9), moderate (10) and severe (41). On‐demand therapy was received by 26 boys, while 18 received low‐dose prophylaxis (HA: 10 IU kg−1 2–3 times week−1, and HB: 20 IU kg−1 1 time week−1). The mean CHO‐KLAT scores were 63.7 (SD = 10.6) for child‐report and 58.3 (SD = 11.4) for parent‐report. Validity was supported by a correlation of 0.67 (P